RT Journal Article
SR Electronic
T1 Evaluation of the antibody response and adverse reactions of the BNT162b2 vaccine of participants with prior COVID-19 infection in Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.18.21260579
DO 10.1101/2021.07.18.21260579
A1 Toshiya Mitsunaga
A1 Yuhei Ohtaki
A1 Yutaka Seki
A1 Masakata Yoshioka
A1 Hiroshi Mori
A1 Midori Suzuka
A1 Syunsuke Mashiko
A1 Satoshi Takeda
A1 Kunihiro Mashiko
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.18.21260579.abstract
AB Introduction Vaccination programs are important to preventing COVID-19 infection. BNT162b2 is new type of vaccine, and previous studies have shown that the antibody response was significantly elevated in patients with prior COVID-19 infection after the first vaccination. However, no study has evaluated the efficacy of the vaccination or the adverse reactions of people with prior COVID-19 infection in Japan. The aim of this study is to evaluate the antibody titer and adverse reactions of BNT162b2 vaccine among participants with prior COVID-19 infection in Japan.Methods The data for this study was collected between April 15, 2021, and June 9, 2021. All of the hospital staff who received the BNT162b2 vaccine were included in this study and were sorted into either the prior infection group or the control group. We collected the data of adverse reactions through self-reporting and calculated the anti-SARS-CoV-2 spike-specific antibody titer for all participants.Results The antibody titer of the prior-infection group in first antibody test was significantly higher than that of the control group in the second antibody test. There was no significant difference in adverse reactions between the prior infection group receiving its first vaccination and the control group receiving its second vaccination.Conclusion Our study shows that the antibody response following the first vaccination in the prior COVID-19 infection group was found to be comparable to that of the second vaccination in the control group; however, the evaluation of adverse reactions was inadequate and further, large-scale studies are needed.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol for this research project was approved by the Ethics Committee of the institution, it conforms to the provision of the Declaration of Helsinki (Committee of the Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, Approval No. 2020-Ack-19) and written consent was obtained from all the participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe permit the use of the data available from the links below. https://www.amazon.co.jp/clouddrive/share/RojSjHadBhY2LHhheayyqxRKphwwV51IP8tXscuA2E8